Author

D. Goldhill

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Organism:virus· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

W. S. Barclay· 4 shared A. Lackenby· 2 shared M. Galiano· 2 shared M. Zambon· 2 shared R. Frise· 2 shared S. Miah· 2 shared A. Gallego-Cortes· 1 shared A. Yan· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

W. S. Barclay

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction

R. P. Galao, H. Wilson, K. L. Schierhorn, F. Debeljak, B. S. Bodmer, D. Goldhill, T. Hoenen, S. J. Wilson, C. M. Swanson, S. Neil

This study identifies TRIM25 and ZAP as key factors in type I interferon-mediated inhibition of Ebola virus replication by targeting the viral ribonucleoprotein complex.

bioRxiv · May 23, 2021Microbiology

Mammalian ANP32A and ANP32B proteins drive alternative avian influenza virus polymerase adaptations

T. P. Peacock, C. M. Sheppard, E. Staller, R. Frise, O. C. Swann, D. Goldhill, J. S. Long, W. S. Barclay

This study identifies alternative PB2 adaptations that enable influenza polymerase to use mammalian ANP32 proteins, with PB2-E627K showing a preference for ANP32B.

bioRxiv · Sep 3, 2020 · PreprintMicrobiology

Favipiravir-resistant influenza A virus shows potential for transmission

D. Goldhill, A. Yan, R. Frise, J. Zhou, J. Shelley, A. Gallego-Cortes, S. Miah, O. Akinbami, M. Galiano, M. Zambon, A. Lackenby, W. S. Barclay

This study shows favipiravir-resistant influenza A virus can transmit in ferrets but may lose its resistance mutation in vivo due to fitness trade-offs.

bioRxiv · Sep 1, 2020Microbiology

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza

C. Scott, J. Kankanala, T. L. Foster, D. Goldhill, K. J. Simmons, M. Pingen, M. J. Bentham, E. Atkins, E.-A. Loundras, R. Elderfield, J. K. Claridge, J. Thompson, R. Stilwell, R. Tathineni, C. S. McKimmie, , S. Griffin

The paper identifies M2-N31 inhibitors that show synergistic antiviral effects when combined with existing drugs, offering a strategy to combat rimantadine-resistant influenza.

bioRxiv · Jul 24, 2019Microbiology

Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation Sequencing

D. Goldhill, P. Langat, H. Xie, M. Galiano, S. Miah, P. Kellam, M. Zambon, A. Lackenby, W. S. Barclay

This study uses next-generation sequencing to determine the mutation bias caused by favipiravir in influenza virus RNA, showing it primarily acts as a guanine analogue and secondarily as an adenine analogue.

bioRxiv · Jul 23, 2018Microbiology